Resources
6 Results (showing 1 - 6)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 3/10/2021 (updated 4/5/2024)
The 2020 National Drug Threat Assessment (NDTA) is a comprehensive assessment of the threat posed to the United States by the trafficking and abuse of illicit drugs, the diversion and abuse of licit drugs, and the laundering of proceeds generated through illicit drug sales. It also addresses the role domestic groups, including organized violent gangs, serve in domestic drug trafficking. The most widely trafficked drugs are discussed in terms of their availability, consumption and overdose related deaths, production and cultivation, transportation, and distribution.
Posted 8/11/2020 (updated 4/2/2024)
Non-fatal opioid overdose (NFOO) is a significant cause of opioid-related morbidity in the United States. As the number of NFOOs continues to grow, it is important to understand the short- and long-term consequences of NFOO. This report examines the existing literature on the acute and chronic health and functional outcomes of individuals who experience NFOO, and also identifies differences in outcomes for NFOOs involving illicitly-manufactured fentanyl.
Posted 5/12/2020 (updated 3/28/2024)
The National Center for Health Workforce Analysis informs public and private-sector decision-making related to the health workforce by expanding and improving health workforce data, disseminating workforce data to the public, improving and updating projections of the supply and demand for health workers, and conducting analyses of issues important to the health workforce.
Posted 5/11/2020 (updated 3/28/2024)
Behavioral health integration, or BHI, requires that the health and mental health systems are organized through integrated care models that address the full spectrum of health needs.
Posted 7/14/2023 (updated 3/28/2024)
The National Conference of State Legislatures (NCSL) provides an overview of programs states have implemented to address or mitigate workforce shortages. The report describes programs across various stages of education, including K-12, community college, and undergraduate programs.
Posted 10/23/2023 (updated 3/27/2024)
The Reagan-Udall Foundation partnered with the Food and Drug Administration (FDA) for the "Mitigating Risks from Human Xylazine Exposure" virtual and in-person webinar that occurred early October 2023. This public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure and examined concrete strategies for drug development and clinical research that directly supports the mitigation and reduction of risks associated with human exposure to xylazine. The meeting materials, recordings, and slides are now available for viewing.